Compare iShares JPMorgan USD Emerging Markets Bond ETF (EMB) vs Hinge Health Inc. Class A Common Stock (HNGE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares JPMorgan USD Emerging Markets Bond ETF vs Hinge Health Inc. Class A Common Stock — how do they compare? iShares JPMorgan USD Emerging Markets Bond ETF trades at $91.23 (market cap $12.73B), while Hinge Health Inc. Class A Common Stock trades at $103.52 (market cap $8.47B). The key difference: iShares JPMorgan USD Emerging Markets Bond ETF is the larger of the two by market cap, and Hinge Health Inc. Class A Common Stock is trading nearer its 52-week high, iShares JPMorgan USD Emerging Markets Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares JPMorgan USD Emerging Markets Bond ETF for 50 Days and Hinge Health Inc. Class A Common Stock for 0 Days on average.
| EMB | HNGE | |
|---|---|---|
Market Cap | $12.73B | $8.47B |
Volume | 9,417,425 | 1,624,526 |
Sector | Fixed Income | Health |
52-Week High | $97.74 | $105.14 |
52-Week Low | $90.14 | $31.17 |
Typical Hold Time | 50 Days | 0 Days |
Enterprise Value | — | $8.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EMB trades at $91.26, up 0.2% over 24 hours, with technical indicators signaling a bearish trend and neutral oscillators. The stock faces resistance at $91 and $92, with support near $90. Recent dividend announcements for H2-26 suggest a focus on shareholder returns, but key valuation and profitability metrics are unavailable.
The outlook remains cautious due to bearish technical signals and limited fundamental data. Risks include market volatility and macroeconomic pressures from rising bond yields. Analyst sentiment is mixed, with some highlighting income potential but warning that significant price appreciation may be limited.
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares JPMorgan USD Emerging Markets Bond ETF
EMB invests in U.S. dollar-denominated sovereign debt from emerging market countries. It provides exposure to government bonds from dozens of nations like Turkey, Mexico, and Brazil, offering a way to seek higher yields and geographic diversification.
Read more on EMB →About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →
